Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells by Paolo, A Di et al.
Post-translational modification of proteins with isoprenoids was
first recognized as a general phenomenon almost two decades ago.
In recent years, the understanding of the enzymatic reactions as-
sociated with these modifications and their functions in physio-
logical and pathological settings has increased dramatically
(Sinensky, 2000). Proteins of the ras superfamily play a pivotal
role in a wide variety of cellular functions, including signal trans-
duction, dynamic organization of the cytoskeleton and cell prolif-
eration (Marshall, 1996). Mutational activation of ras genes results
in uncontrolled growth and malignant transformation, and ras
mutants have been discovered in at least 30% of all human
neoplasms (Minamoto et al, 2000). Both wild-type and mutated
p21ras proteins require post-translational isoprenylation for proper
localization within cellular compartments, and these reactions
are catalysed by specific enzymes, the farnesyl-transferase (FTase)
(Sinensky, 2000). The development of inhibitors of ras farnesyla-
tion was a logical consequence of biological research and has been
translated in the clinical setting for the treatment of human malig-
nancies (Rowinsky et al, 1999; Zujewski et al, 2000). However,
the model of cancerogenesis due to deregulated ras-dependent
pathway has increased its complexity in recent years, because of
the discovery of multiple ras-related signalling pathways with
different downstream effectors that control cell proliferation,
differentiation and apoptosis (Campbell et al, 1998). Among these
pathways are those that connect ras to members of rho family of
GTPase proteins, which are regulators of actin organization and
cell cycle progression (Zohn et al, 1998; Kaibuchi et al, 1999). A
number of experimental observations suggested that rho and rac
proteins are necessary for cell transformation by oncogenic ras
proteins (Olson et al, 1995, 1998; Prendergast et al, 1995), because
some characteristics of malignant phenotype seem to be dependent
on deregulation of rho and rac functions (Zohn et al, 1998). For
these reasons, the use of FTase inhibitors may not be fully effec-
tive to control cell proliferation, because geranylgeranylated
proteins, including rho, rac and CDC42, play a pivotal role in
G1–S-phase transition of cells committed to mitosis (Olson et al,
1995; Lebowitz and Prendergast, 1998). Indeed, the treatment with
inhibitors of the enzymes geranylgeranyl-transferase (GGTase) I
and II causes cells to arrest at the G1–S boundary (Miquel et al,
1997) and suppresses cyclin-dependent kinase (cdk) activity (Sun
et al, 1999). Of note, p21rhoA is involved in G protein-coupled
receptor signal transduction (Seasholtz et al, 1999; Sah et al,
2000), and the cellular response to selected growth factors,
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geranylation rather than farnesylation (McGuire et al, 1996).
Finally, cellular proteins, including K-rasB, may be activated
through geranylgeranylation, if the FTase activity is impaired, thus
reducing treatment efficacy of FTase inhibitors (Vogt et al, 1996).
On these premises, it appears that targeting isoprenylation as a
means of controlling cancer cell growth requires the inhibition of
both GGTase and FTase for optimal activity. 
The inhibition of GGTase may be obtained by compounds that
mimic the isoprenylation consensus sequence at the carboxylic
terminal of proteins (Vogt et al, 1996; Sun et al, 1998). However,
novel GGTase inhibitors have been recently obtained, chemically
derived from geranylgeranyl diphosphate (GGPP), in which the
biologically labile diphosphate moiety of GGPP, the natural
substrate of GGTase, has been replaced by stable isosters
(Macchia et al, 1996, 1997). Therefore, the aim of the present
study was to investigate the effect of BAL9611, a synthetic
analogue of GGPP with potent inhibitory activity on protein
geranylgeranylation, on signal transduction through ras proteins
and proliferation of the human cancer cell line SW620 in vitro and
in vivo, and whether the combined treatment with manumycin, a
specific FTase inhibitor, enhances the chemotherapeutic activity of
BAL9611. 
MATERIALS AND METHODS 
Drugs and chemicals 
Antipain, leupeptin, aprotinin, SDS and proteinase K were
purchased from Boehringer Mannheim GmbH (Mannheim,
Germany); cell culture media were from HyClone (Cramlington,
UK); agarose and 180 bp DNA ladder were purchased from Gibco
(Gaithersburg, MD, USA) and acrylamide was from International
Biotechnologies Inc (New Haven, CT, USA). DEA and Nonidet P-
40 were obtained from ICN Biomedicals Inc (Costa Mesa, CA,
USA); mouse IgG1 anti-pan21ras monoclonal antibody was
purchased from Transduction Laboratories (Lexington, KY, USA),
anti-p21rhoA and anti-p42ERK2/MAPK rabbit polyclonal anti-
bodies were from Santa Cruz Biotechnology Inc (Santa Cruz, CA,
USA). Horseradish peroxidase-conjugated secondary antibodies
and reagents for chemiluminescence detection of proteins in
immunoblots (ECL Western detection system) were purchased
from Amersham Life Science (Little Chalfont, UK). Bisbenzimide
trihydrochloride (Hoechst 33258) was from Sigma as well as all
other chemicals (St Louis, MO, USA). 
The tripotassium salt of (E,E,E)-1-ethyl-1-[(4,8,12,16-tetra-
methyl-3,7,11,15-heptadecatetraenyl)hydroxyphosphoryl]-pro-
pylphosphonic acid (BAL9611, Figure 1) was synthesized at the
department of Pharmaceutical Sciences, University of Pisa
(Macchia et al, 1996). The drug was dissolved in water/ethanol
(50:50, v/v) at 10 mM and stored at –20˚C. Manumycin (Figure 1)
was kindly provided by Dr M Hara, Kyowa Hakko Kogyo Co
(Tokyo, Japan); the drug was dissolved in sterile distilled water
containing DMSO 0.05% at 10 mM concentration, and stored at
–20˚C. Manumycin and BAL9611 were diluted in sterile culture
medium immediately before their use. 
Cell culture 
The human colorectal cancer cell line SW620 was obtained from
the American Type Culture Collection (Rockville, MD, USA).
SW620 cells were maintained in RPMI 1640 medium, supple-
mented with 10% FBS, penicillin (50 IU ml–1), streptomycin 
(50 mg ml–1) and L-glutamine (2 mM). Cells were grown in 75 cm2
tissue culture flasks (Nunc, Roskilde, Denmark) and kept in a
humidified atmosphere of 5% CO2 at 37˚C. Cells were harvested
with 2 mM EDTA when they were in log phase of growth, 
and maintained at the above-described culture conditions for all 
experiments. 
PCR analysis of K-ras sequence in SW620 cell line 
The analysis of the codon 12 of K-ras gene was performed 
in SW620 cells by oligodeoxynucleotide hybridization, as previ-
ously described (Marchetti et al, 1997). The primers used to amp-
lify the K-ras gene upstream and downstream codon 12 
were as follows: 5¢-GGCCTGCTGAAAATGACTGA-3¢ and 
5¢-TGATTCTGAATTAGCTGTAT-3¢. The PCR reaction was per-
formed as follows: initial denaturation, 4 min at 94˚C; amplifica-
tion, 30 s at 94˚C, 30 s at 54˚C and 1 min at 72˚C for 35 cycles;
elongation, 10 min at 72˚C. The amplified products of the PCR
reaction were denatured, blotted onto nylon membranes and then
hybridized with 32P-labelled oligonucleotide probes specifically
designed to detect ras mutations (Marchetti et al, 1997). 
Immunoblot analysis of p21ras farnesylation, p21rhoA
geranylgeranylation and p42ERK2/MAPK
phosphorylation 
SW620 cells were exposed to BAL9611 0.01–1 mM or
manumycin 1 mM for 72 h to document their effect on p21rhoA
geranylgeranylation, while p21ras farnesylation was evaluated in
cells treated with manumycin 1–10 mM or BAL9611 at 0.1 mM for
72 h. Cells exposed to drugs and untreated controls were harvested
with 2 mM EDTA and washed thrice with phosphate-buffered
saline (PBS), pH 7.4, and finally solubilized at 4˚C for 45 min in
Tris-base 50 mM, pH 7.6, 2 mM EDTA, 100 mM NaCl, 1% (v/v)
Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride (PMSF) and
2 mg ml–1 each of aprotinin, pepstatin and antipain and the protein
phosphatase inhibitors sodium metavanadate and sodium fluoride
(200 mM each). Cell lysate was then centrifuged at 15 000 rpm for
20 min, and the pellet was discarded. Aliquots of supernatants
were used to measure protein concentration, and the remaining
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Figure 1 Chemical structure of BAL9611 and manumycin samples were used for immunoblot analysis. Samples (40 mg each)
were boiled for 5 min in SDS-sample buffer (50 mM Tris-base 
pH 6.8, 2% sodium dodecyl sulfate (SDS), 100 mM dithiothreitol,
10% glycerol and 0.025% b-mercaptoethanol) and separated on
15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Blots
were probed with anti-p21ras or anti p21rhoA antibodies (1:500
and 1:1000, respectively), and detected with the use of horseradish
peroxidase-conjugated secondary antibody (dilution, 1:1000)
(Danesi et al, 1995, 1996). The membranes were then exposed to a
Kodak X-Omat AR film, and optical densities of films obtained in
nine independent experiments were quantified as described below
in Analysis of data. The effect of drugs on p42ERK2/MAPK phos-
phorylation was evaluated in SW620 cells treated with BAL9611
0.01–1 mM, manymycin 1 mM and with BAL9611 0.01 mM plus
manumycin 0.1 mM for 72 h. Cells were harvested and solubilized
as reported above; cellular lysates were centrifuged for 20 min at
15 000 rpm, and aliquots of supernatants were separated to
measure protein concentration. Equivalent amounts of cellular
proteins (40 mg) were separated on 15% SDS-PAGE (Danesi et al,
1995, 1996), transferred onto Immobilon-P membrane, probed
with anti-p42ERK2/MAPK antibody (dilution, 1:1000), and de-
tected as described above. Optical densities of films obtained in nine
independent experiments were quantified as described below in
Analysis of data. 
Assay of apoptosis by BAL9611 and manumycin 
To demonstrate whether BAL9611 and manumycin were able to
trigger apoptosis, SW620 cells were treated with BAL9611 0.01–1
mM or manumycin 1 mM for 72 h. Cells were harvested with
EDTA 2 mM, washed thrice with PBS, pH 7.4, and of 3 ´ 106 cells
for each drug concentration were centrifuged at 2000 rpm for 15
min. Cells were solubilized in TE buffer (1 mM EDTA, 10 mM
Tris-base, pH 7.5) containing 0.2% (v/v) Triton X-100 for 90 min
at 4˚C. Samples were centrifuged at 15 000 rpm for 1 h at 4˚C and
clear supernatants containing fragmented chromatin were incu-
bated at 42˚C for 30 min with proteinase K (200 mg ml–1) and then
diluited 1:1 in phenol:chloroform:isoamyl alcohol, vigorously
shaken for 30 s, and centrifuged at 15 000 rpm for 10 min.
Supernatants were again collected and mixed with 100 ml of NaCl
5 M, 1 ml of cold ethanol, and 1 ml of glycogen. The suspensions
were kept at –20˚C overnight to precipitate DNA fragments and
then centrifuged at 15 000 rpm for 30 min; the supernatants were
discarded and the pellets were washed with 70% ethanol and dried
under air flow. 
Each sample was resuspended in TE buffer (1 mM EDTA,
10 mM Tris-base, pH 7.5), containing 1 mg ml–1 boiled bovine
pancreatic RNAse A, incubated at 40˚C for 60 min, and mixed
with DNA sample buffer (15 mM EDTA pH 8.0, 0.1% SDS,
0.025% xylene cyanole, 0.025% bromophenol blue and 0.5% glyc-
erol). Separation of DNA fragments was obtained by electro-
phoresis in 1% agarose gel, in TAE buffer (Tris-base 32 mM, 1%
glacial acetic acid and 1 mM EDTA); bands were visualized
by ethidium bromide staining under UV light and the gels were
photographed with a Polaroid MP4 Land camera (Polaroid,
Cambridge, MA, USA). 
Moreover, the induction of apoptosis by BAL9611 and
manumycin in SW620 cells was further demonstrated by staining
with bisbenzimide trihydrochloride (Hsueh et al, 2000). Briefly,
cells were harvested by trypsin-EDTA, washed twice in PBS, fixed
in 3% paraformaldheyde and incubated at room temperature for 
10 min. Then cells were washed with PBS, resuspended in PBS
containing 8 mg ml–1 of bisbenzimide trihydrochloride and incu-
bated for 15 min at room temperature. Aliquots of cell suspension
were placed on sylanized microscope glass slides and cells were
counted and scored for incidence of apoptotic features (i.e., chro-
matin condensation, nucleus fragmentation) using a Leica micro-
scope (Leica, Germany). The apoptotic index (AI) was calculated
as the percentage ratio between the number of cells displaying
apoptotic features and the total number of counted cells. 
Analysis of cytotoxicity and drug interaction 
To evaluate the effect of BAL9611 and manumycin alone and in
combination on SW620 cell growth, as well as the type of interac-
tion with respect to cytotoxicity, SW620 cells were seeded at 1.5 ´
106 cells well–1 in 60-mm sterile dishes for cell culture, in a final
volume of 3 ml well–1, and incubated at 37˚C in 5% CO2. After 
48 hours, cells were treated with BAL9611 0.01–10 mM and
manumycin 0.01–25 mM alone or in combination for 72 h; for
comparison, separate cell cultures were given 5-fluorouracil 
(5-FU) 0.01–100 mM. At the end of experiment, cultures were
harvested with 2 mM EDTA and the number of surviving cells was
counted by haemocytometer. The inhibitory concentration of
BAL9611 and manumycin on cell growth at the 50% level (IC50)
as well as the type of drug interaction were assessed in nine inde-
pendent experiments as described in Analysis of data. 
In vivo studies 
The chemotherapeutic effect of BAL9611 and manumycin in vivo
was investigated in athymic mice. Briefly, SW620 cells in log-
phase of growth, maintained at the above-mentioned culture
conditions, were harvested by scraping and 107 cells were resus-
pended in serum-free RPMI-1640 culture medium. Cells were
injected subcutaneously between the scapulae of 7-week-old
female CD nu/nu mice (Harlan Nossan, Comerio, Italy). Mice
were housed in laminar-air-flow caging system (Techniplast,
Buguggiate, Italy) and provided with sterilized water, food and
bedding ad libitum. Tumour masses became detectable 3 days after
cell inoculum and mice were randomly divided in 4 groups of 6
animals each. Mice were given i.p. BAL9611 10 mg kg–1 and
manumycin 8 mg kg–1, alone or in combination, or vehicle (control
group), daily for 5 days. The dose of BAL9611 was chosen on the
basis of preliminary experiments aimed at defining a treatment
schedule with significant antitumor activity and tolerable toxicity,
while manumycin dosing was selected on the basis of a previous
report (Hara et al, 1993). Tumour growth was evaluated daily, by
measuring the size of each mass, and its volume (V) was calcu-
lated as follows: V = 1/2 ´ A ´ B2, where A and B are the tumour
length and width (in mm), respectively (Tomayko and Reynolds,
1989). Tumour growth was monitored for further 3 weeks after the
end of treatment, after which mice were sacrified, and tumours
were explanted and measured. 
In order to demonstrate the induction of apoptosis by drugs in
xenografts, H&E-stained section of tissue specimens were exam-
ined using light microscopy for morphological evidence of
apoptosis. Briefly, following the above described experimental
conditions, 16 female CD nu/nu mice were injected with 107
SW620 cells/mouse between scapulae, and treatment started when
tumour mass became palpable. Mice were treated at the same
dosages described above for 5 consecutive days (4 mice/group),
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in paraffin, and 3-mm sections were obtained. Specimens were
stained with H&E and cells were counted and scored for the occur-
rence of morphological evidence of apoptosis (Gandhi et al, 1998).
Again, the apoptotic index (AI) was calculated as the percentage
ratio between the number of cells displaying apoptotic features
and the total number of cells counted. 
Analysis of data 
The effects of BAL9611 and manumycin on protein isoprenylation
as well as on kinase phosphorylation were assessed by capturing
the images corresponding to the non-isoprenylated (p21ras and
p21rhoA) or phosphorylated (p42ERK2/MAPK) protein bands in
the immunoblotting (upper position) and isoprenylated or non-
phosphorylated protein bands (lower position in the immunoblots).
Film densities of protein blots were examined with the Kontron
Imaging analysis system KS300 (Kontron Elektronic, Eching,
Germany) connected to a TK-1280E colour video camera (JVC,
Tokyo, Japan), and expressed as mean percentage ± standard error
(SE) of arbitrary units of grey values with respect to controls (Di
Paolo et al, 2000). In order to compensate for the decrease in
protein synthesis as a consequence of treatment of cells with test
compounds, the inhibitory effect of BAL9611 and manumycin on
p21ras and p21rhoA isoprenylation as well as on p42ERK2/MAPK
phosphorylation was expressed as the ratio of isoprenylated/phos-
phorylated versus non-isoprenylated/non-phosphorylated bands.
The non-linear least squares curve fitting of the experimental data
of protein immunoblots (ratios of modified vs. unmodified proteins)
allowed the calculation of the drug concentration producing a 50%
decrease (IC50) in the isoprenylation or phosphorylation of target
proteins. The proliferation of treated cells was expressed as the
mean percent values ±SE of cell numbers counted at the end of the
experiment with respect to untreated controls. Experimental data
were modelled by non-linear least squares curve fitting in order to
obtain the drug concentration that produced a 50% inhibition
(IC50) of SW620 cell proliferation. In addition to this, the type of
drug interaction in the combined treatment was analysed at the
50% isoeffect level by using the isobologram method previously
described (Steel and Peckham, 1979; Greco et al, 1995). Briefly, 3
isoeffect curves (isobolograms) were constructed: mode I in the
case of independent mechanism of drug action (heteroaddition),
and mode IIa and IIb if BAL9611 and manumycin were acting by
a similar mechanism (isoaddition). Regardless of the mechanism
of action of drugs, the combination was considered to be additive
if data points of the drug combination are included in the area
surrounded by 3 lines (envelope of additivity). On the contrary, if
experimental data fall to the left or to the right of the envelope, the
combined effect of 2 drugs is greater (supra-additive, synergism)
or lower (sub-additive) than the sum of single drug effects, respec-
tively. Finally, if point coordinates are greater than IC50 values of
one or both drugs, the combined effect is lower than the effect of a
single pharmacological agent (protection). Both sub-additive and
protective effects were considered to be antagonistic. 
All results are obtained in triplicate sets of experiments, each
done in triplicate and results are given as mean values ± SE. The
two-tail unpaired Student’s t-test or ANOVA followed by the
Student–Newmann–Keuls test were used to assess statistical
differences of data obtained in control and treated cells with respect
to immunoblotting, apoptosis and in vitro and in vivo cytotoxicity
studies. P values lower than 0.05 were considered significant. 
RESULTS 
K-ras gene mutation in SW620 cells 
Mutated K-ras oncogenes are frequently found in colon cancers,
and for this reason the analysis of K-ras gene sequence in SW620
cell line was performed. Indeed, SW620 tumour cells displayed a
GGT (Gly) ® GTT (Val) point mutation at codon 12 of one allele,
as shown by dot blot analysis with mutation-specific probes. 
Inhibition of p21rhoA geranylgeranylation, p21ras
farnesylation and p42ERK2/MAPK phosphorylation by
BAL9611 and manumycin 
Western blot analysis showed that BAL9611 and manumycin
inhibited the geranylgeranylation and farnesylation of p21rhoA
(Figure 2) and p21 ras (Figure 3), respectively. In particular,
BAL9611 reduced dose-dependently the optical density of the
lower protein band of each lane, corresponding to the geranylger-
anylated p21rhoA (Figure 2A), with significant effect starting
from 0.1 mM (Figure 2B). Although some reduction in the bands
of p21rhoA was observed while increasing the concentration of
BAL9611 in the culture medium, image analysis demonstrated
that the geranylgeranylated protein was reduced more than the
non-geranylgeranylated p21rhoA, thus resulting in a ‘true’ dose-
dependent impairment of protein geranylgeranylation (Figure 2B),
not influenced by variations of protein synthesis in cells treated
with BAL9611. The calculation of the IC50 by fitting the optical
density ratios provided a value of 0.21 ± 0.03 mM. On the contrary,
the geranylgeranylation of p21rhoA was unaffected by manu-
mycin 1 mM for 72 h (Figure 2A and 2B), a drug concentration
that was indeed able to inhibit p21ras farnesylation (Figure 3).
Manumycin dose-dependently inhibited the isoprenylation of
p21ras, as demonstrated by the immunoblots showing a progressive
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Figure 2 Western blot analysis (A) of p21rhoA from cells treated with
BAL9611 0.01–1 mM or manumycin 1 mM for 72 h and (B) image analysis of
geranylgeranylated (GG) vs. non-GG isoforms of p21rhoA. Columns: mean
values; vertical bars: S.E.; *P < 0.05 vs. control (C) values enrichment in the upper band of non-farnesylated peptide (Figure
3A), whereas BAL9611 0.1 mM did not impair the farnesylation of
p21ras (Figure 3A and B). As also observed for BAL9611, the
ratio between the 2 protein bands that were detected in p21ras
immunoblots indicated that the inhibition of farnesylation was not
related to the reduction in p21ras abundance in cancer cells as a
result of drug treatment (Figure 3A and B), and the calculated IC50
value of manumycin was 2.99 ± 0.59 mM. Finally, the phosphory-
lation of p42ERK2/MAPK was reduced dose-dependently by
BAL9611 and manumycin (Figure 4A), and the decrease was
confirmed by the assessment of the ration between the phosphory-
lated and non-phosphorylated protein bands (Figure 4B). At the
concentration of 0.01 mM BAL9611 and 0.1 mM manumycin, the
relative amount of phosphorylated p42ERK2/MAPK was inhib-
ited by 9.83 ± 3.55% and 2.29 ± 0.42% (Figure 4C and D), respec-
tively, as compared to untreated controls, whereas the combined
treatment at the same drug concentrations reduced the phosphoryl-
ation of p42ERK2/MAPK by 52.68 ± 5.47% (Figure 4C and 4D). 
BAL9611 and manumycin induce apoptosis in SW620
cells 
The occurrence of apoptosis was demonstrated by the recovery
of small fragmented DNA from the cytoplasm of cells treated with
isoprenylation inhibitors. The analysis by agarose gel electrophoresis
showed the presence of a distinctive DNA laddering with fragments
of multiple of the internucleosomal length of 180 bp after treat-
ment with BAL9611 0.01–1 mM or manumycin 1 mM (Figure 5A).
These results were confirmed by the assessment of the AI in
SW620 cells exposed to the same concentrations of BAL9611 and
manumycin. In treated cells the staining with the compound
Hoechst 33258 ensured the detection of early and late phases of
apoptosis. In fact, the AI was significant higher in cells treated
with BAL9611 0.1 to 1 mM or manumycin 1 mM than in controls
(Figure 5B), and the induction of apoptosis was dose-dependent in
the case of BAL9611. In agreement with the in vitro data, results
obtained in SW620 xenografts revealed that both drugs were able
to induce apoptosis, due to the presence of perinuclear condensa-
tion of chromatin, cytoplasmic budding, cell shrinkage and,
finally, formation of apoptotic bodies, as observed in H&E-stained
sections. The AI was significant higher in xenografts treated with
BAL9611 plus manumycin with respect to controls, and the
combined treatment was superior to single agents (Figure 5B).
Finally, BAL9611 was more effective in inducing apoptosis in
xenotransplanted SW620 cells than manumycin (AI values, 13.5 ±
1.2 and 11.3 ± 0.9, respectively), and it was in agreement with the
Inhibition of farnesylation enhances cytotoxicity of BAL9611 1539
British Journal of Cancer (2001) 84(11), 1535–1543 © 2001 Cancer Research Campaign
C 1 2 5 10 0.1
non-F
p21ras
BAL9611 
(mM)
Manumycin (mM)
A
F
*
*
*
*
0
25
50
75
100
125
p
2
1
r
a
s
 
F
/
n
o
n
-
F
 
r
a
t
i
o
(
%
 
o
f
 
c
o
n
t
r
o
l
s
)
C 1 2 5 10 0.1
Manumycin (mM) BAL9611
 (mM)
B
Figure 3 Western blot analysis (A) of p21ras from cells treated with
manumycin 1–10 mM or BAL9611 0.1 mM for 72 h and (B) image analysis of
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with BAL9611 0.01–1 mM or manumycin 1 mM for 72 h and (B) image
analysis of phosphorylated (P) vs. non-P isoforms of p42ERK2/MAPK.
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Effect of combined treatment with BAL9611 and manumycin on
p42ERK2/MAPK phosphorylation: Western blot analysis (C) and image
analysis (D) of control cells (C), and cells treated with BAL9611 0.01 mM (B),
manumycin 0.1 mM (M) or combination (B+M). Columns: mean values;
vertical bars: S.E.; *P < 0.05 vs. control (C) values lower IC50 value of the GGTase inhibitor with respect to
manumycin. 
Synergistic inhibition of SW620 cell proliferation by
BAL9611 and manumycin 
BAL9611, manumycin and 5-FU reduced SW620 cell prolifera-
tion in a dose-dependent manner (Figure 6), and the IC50 values
were 0.49 ± 0.03 mM, 2.73 ± 0.38 mM and 5.24 ± 1.41 mM, respec-
tively. The isobologram analysis of drug interaction between
BAL9611 and manumycin demonstrated that BAL9611 0.01–10
mM in combination with increasing concentrations of manumycin,
from 0.1 to 5 mM, shifted the survival curve of SW620 cells
toward the left in the semilogarithmic plot (Figure 7). The IC50
values of BAL9611 in the combined treatment for increasing
concentrations of manumycin from 0.1 to 5 mM were: 0.47 ± 0.11
and 0.19 ± 0.02 mM, 65.0 ± 5.3, 4.2 ± 0.09 and 3.3 ± 0.06 nM,
respectively (P < 0.05 with respect to BAL9611 alone). The results
obtained from the isobologram analysis performed at the 50%
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Figure 6 Dose-dependent inhibition of SW620 cell proliferation by
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Figure 7 Dose-dependent enhancement of BAL9611 cytotoxicity by
manumycin 0.1–5 mM. Points: mean values; C, controls; SE values are lower
than 5% of the respective mean values isoeffect level demonstrated that the combined treatment of
BAL9611 plus manumycin was synergistic, because the ex-
perimental IC50 values of the combination fell to the left of the
envelope of additivity (Figure 8). 
Enhanced growth inhibition of SW620 cells in vivo by
BAL9611 and manumycin 
SW620 cells injected s.c. in CD nu/nu mice grew rapidly and
tumour masses became detectable 3 days after xenotransplanta-
tion. Tumours in control animals showed a progressive enlarge-
ment in their dimensions, and a mean volume of 900 mm3 was
reached at the end of the experimental period (Figure 9). Both
BAL9611 and manumycin were able to inhibit tumour growth, and
their chemotherapeutic effect was significant starting on the 21st
day after implant as compared to controls (Figure 9). In the group
of animals receiving the combined treatment with BAL9611 and
manumycin, the reduction in tumour growth was significant on
day 14 with respect to controls (Figure 9). The tumour growth
curve of BAL9611+manumycin showed a moderate increase,
divergent from that of controls, as well as from BAL9611– and
manumycin-treated animals, and at day 21 and 28 the tumour
volume was significantly different from that of controls and of
animals given BAL9611 and manumycin alone (Figure 9).
DISCUSSION
The present study provides evidence that the cytotoxic effect of the
geranylgeranyltransferase inhibitor BAL9611 is enhanced in vitro
and in vivo on SW620 colon cancer cells by combination with
manumycin, an inhibitor of protein farnesylation. These data
support the evidence that optimum chemotherapeutic effect of
inhibitors of protein isoprenylation is obtained when FTase and
GGTase inhibitors are combined, in order to target both types of
post-translational modification of proteins. In this study, the syner-
gistic cytotoxic effect on SW620 human colorectal cancer cells by
BAL9611 and manumycin was associated with inhibition of
isoprenylation of p21ras and p21rhoA proteins, with enhanced
inhibition of p42ERK2/MAPK phosphorylation. The targeting of
ras-dependent signal transduction pathway to inhibit cancer cell
proliferation is a promising approach for the therapy of human
neoplasms, due to the important role of ras and ras-like proteins in
transducing mitogenic signals from cell membrane to the nucleus
(Marshall, 1996; Sinensky, 2000). However, due to the large
number of proteins which undergo isoprenylation, it is possible
that the antiproliferative effect of FTase and GGTase inhibitors
could depend also on the interference on all those biochemical
pathways which require farnesylated or geranylgeranylated pro-
teins to proceed, as well as proteins involved in cell trafficking,
mitotic spindle function, nuclear envelope and signal transduction
(Fu and Casey, 1999).
BAL9611 is a novel cell-permeable GGPP analogue endowed
with specific inhibitory activity on the GGTase of whole cells
(Macchia et al, 1996); this compound is able to impair the post-
translational isoprenylation of p21rhoA protein in SW620 cells as
well as p42ERK2/MAPK phosphorylation, as demonstrated by the
present results. The inhibitory effect of manumycin on p21ras
farnesylation and signal transduction through p42ERK2/MAPK
pathway has been previously documented in cell lines harbouring
wild-type (Di Paolo et al, 2000) or mutated K-ras gene (Kainuma
et al, 1997). The present evidence that the phosphorylation of
p42ERK2/MAPK may be decreased by the GGTase inhibitor
BAL9611 suggests that p42ERK2/MAPK activity may be modu-
lated by geranylgeranylated proteins, such as p21rhoA. Therefore,
the cooperation between p21ras and p21rhoA appears to be of rele-
vance in the convergent activation of p42ERK2/MAPK, and the
use of farnesylation and geranylgeranylation inhibitors appears to
be a logical approach for maximum effect on the common kinase
pathway located downstream of ras and ras-like proteins. This
hypothesis has been confirmed in the present study in SW620 cells
exposed to BAL9611 and manumycin, because the combined
treatment significantly reduced the phosphorylation of p42ERK2/
MAPK with respect to single drugs. The inhibition of both
geranylgeranylation and farnesylation of ras proteins by BAL9611
and manumycin induced cell death by apoptosis, as revealed by the
typical internucleosomal fragmentation of DNA observed in
treated cells and the occurrence of perinuclear chromatin conden-
sation, cytoplasm budding and nuclear fragmentation, as evidenced
by in vitro and in vivo microscopic studies. The cytotoxic effect
Inhibition of farnesylation enhances cytotoxicity of BAL9611 1541
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manumycin alone displayed by BAL9611 in vitro against SW620, a human
colorectal cancer cell line harbouring a K-ras mutation at codon
12, was superior to that of manumycin. This finding underscores
the important role of geranylgeranylated proteins, and of p21rho
proteins in particular, in the maintenance of a malignant phenotype
by cells harbouring a mutated ras gene (Prendergast et al, 1995)
and in the promotion of cell proliferation (Hirai et al, 1997; Sun et
al, 1998). In addition, the impairment of the function of integrated
pathways originating from p21ras and p21rhoA proteins obtained
by exposing cells to BAL9611 and manumycin resulted in a
marked reduction of tumour growth. The cytotoxic activity of
BAL9611 compares well with that of other inhibitors of protein
geranylgeranylation, including GGTI-298 (Miquel et al, 1997).
The enhanced chemotherapeutic activity of BAL9611 may be
dependent on several factors, including effective inhibition of
GGTase and improved diffusion through the cell membranes due
to the lipophilic structure of BAL9611, as compared to
peptidomimetic drugs inhibitors of GGTase, whose in vitro high
potency on isolated enzyme is counterbalanced by relatively high
doses required in vivo to obtain antitumor effect (Sun et al, 1999).
The present study provides the first evidence of the effective inhi-
bition of tumour cell growth by a combination of GGTase and
FTase inhibitors containing isoprenoid moieties, since most
studies on isoprenylation inhibitors fell short of this experimental
evidence. The cytotoxic effect of BAL9611 was synergistically
enhanced in vitro by increasing concentrations of manumycin, as
confirmed by the shift of the SW620 cell survival curve towards
the left, with lower IC50 values with respect to single drug treat-
ments. The isobologram analysis demonstrated that the combina-
tion was highly synergistic, and this finding confirmed the
hypothesis that the cytotoxicity of BAL9611 and manumycin
depends on the inhibition of both p21ras and p21rhoA proteins,
which are involved in signal transduction, gene expression and cell
proliferation (Zohn et al, 1998), by means of integrated pathways,
which converge on the downstream effector p42ERK2/MAPK, as
also demonstrated by the present results. 
The ras proteins expressed in animal cells are encoded by H-ras,
N-Ras and K-Ras genes; the latter gene generates p21K-rasA and
p21K-rasB for alternative splicing of the fourth exon, which
encodes the prenylation consensus sequence; the B isoform is the
predominant version produced by this gene (James et al, 1995,
1996). Ras proteins resemble each other closely with the exception
of their COOH-terminal tetrapeptides that are designated as
CAAX boxes in which C is cysteine, A stands for an aliphatic
amino acid, and X is a variable amino acid that dictates the relative
specificity of the proteins for the 2 prenyltransferases FTase and
GGTase. In particular, the following sequences are specific to ras
proteins: CVIM (K-RasB), CIIM (K-RasA), CVVM (N-Ras), and
CVLS (H-Ras) (James et al, 1995, 1996). Mutations have been
identified in all 3 ras genes, in about 30% of all human tumours,
including 50% of colon cancers and 90% of pancreatic cancers
(Minamoto et al, 2000) and mutations in K-RasB are by far the
most frequent in human tumours. Oncogenic K-RasB appears to
be farnesylated in transformed cells; however, K-RasB, but not H-
Ras, is also a substrate for CAAX GGTase-I, and its affinity for the
enzyme is equal to that of p21rap1B, an authentic leucine-termi-
nated substrate for GGTase-I (James et al, 1995, 1996). Therefore,
p21K-rasB might become geranylgeranylated when farnesylation
is blocked by a farnesyltransferase inhibitor. Indeed, geranylger-
anylated p21K-rasB has transforming potential similar to the
farnesylated version (James et al, 1996). For these reasons, the
exposure of cells to FTase and GGTase is required to block p21K-
rasB function, even if the present Western blot assays suggested
that in cells exposed to manumycin the possible geranylgeranyla-
tion of K-ras was uneffective in order to counteract the cell growth
by the FTase inhibitor. 
Finally, the administration of BAL9611 and manumycin to nude
mice reduced the proliferation of xenotransplanted SW620 cells,
in agreement with results obtained in vitro. Although tumours
displayed a rather fast regrowth after the discontinuation of single
drug administration, this effect was much less evident with the
combination treatment; therefore future trials should be designated
to achieve a sustained inhibition of isoprenyltransferases by a
protracted treatment for enhanced control of tumour growth. 
In conclusion, the antitumor effect of the geranylgeranylation
inhibitor BAL9611 is enhanced by blocking farnesylation and this
evidence is based on sound biologic principles; in particular, the
data of the present study suggest that isoprenylation of protein
should be targeted at both geranylgeranylation and farnesylation
for optimal antitumor effect. 
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